$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

$ctxr Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023067024 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.242M	$4.907M	$4.028M
YoY Change	96.14%	21.82%	6.55%
% of Gross Profit
Research & Development	$2.883M	$3.765M	$4.888M
YoY Change	-25.27%	-22.98%	121.81%
% of Gross Profit
Depreciation & Amortization	$2.670K	$630.00	$730.00
YoY Change	265.75%	-13.7%	-3.95%
% of Gross Profit
Operating Expenses	$10.12M	$8.672M	$8.917M
YoY Change	34.11%	-2.74%	49.0%
Operating Profit		-$8.672M	-$8.917M
YoY Change		-2.74%	49.0%
Interest Expense	$324.8K	$336.8K
YoY Change	140.9%
% of Operating Profit
Other Income/Expense, Net		$336.8K	$0.00
YoY Change			-100.0%
Pretax Income	-$9.800M	-$8.335M	-$8.864M
YoY Change	32.17%	-5.96%	52.19%
Income Tax	$144.0K	$144.0K
% Of Pretax Income
Net Earnings	-$11.10M	-$8.479M	-$8.864M
YoY Change	38.85%	-4.34%	52.19%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.06	-$0.06
Diluted Earnings Per Share	-$0.07	-$0.06	-$0.06
COMMON SHARES
Basic Shares Outstanding	158.9M shares	158.9M shares	146.1M shares
Diluted Shares Outstanding		153.8M shares	146.1M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.48M	$33.28M	$48.04M
YoY Change	-36.51%	-30.73%	-58.46%
Cash & Equivalents	$26.48M	$33.28M	$48.04M
Short-Term Investments
Other Short-Term Assets	$7.890M	$7.832M	$2.790M
YoY Change	176.57%	180.7%	119.47%
Inventory
Prepaid Expenses	$7.890M	$7.832M	$2.790M
Receivables
Other Receivables
Total Short-Term Assets	$34.37M	$41.11M	$50.83M
YoY Change	-22.87%	-19.12%	-56.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.432K	$2.010K	$4.831K
YoY Change	-65.07%	-58.39%	-99.45%
Goodwill	$9.347M	$9.347M	$9.347M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$38.06K	$38.06K	$38.06K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$69.24M	$69.29M	$69.48M
YoY Change	-0.28%	-0.27%	134.28%
TOTAL ASSETS
Total Short-Term Assets	$34.37M	$41.11M	$50.83M
Total Long-Term Assets	$69.24M	$69.29M	$69.48M
Total Assets	$103.6M	$110.4M	$120.3M
YoY Change	-9.11%	-8.24%	-17.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.927M	$3.080M	$1.691M
YoY Change	151.19%	82.17%	24.79%
Accrued Expenses	$476.3K	$892.9K	$1.301M
YoY Change	-66.11%	-31.38%	-37.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.779M	$5.791M	$4.461M
YoY Change	27.57%	29.81%	23.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$262.9K	$320.0K	$532.9K
YoY Change	-45.38%	-39.95%	-26.48%
Total Long-Term Liabilities	$262.9K	$320.0K	$532.9K
YoY Change	-45.38%	-39.95%	-26.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.779M	$5.791M	$4.461M
Total Long-Term Liabilities	$262.9K	$320.0K	$532.9K
Total Liabilities	$12.18M	$12.10M	$9.980M
YoY Change	15.2%	21.29%	0.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$162.2M	-$152.3M	-$121.7M
YoY Change	25.09%	25.14%
Common Stock	$158.9K	$158.9K	$146.1K
YoY Change	8.65%	8.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$90.83M	$97.70M	$109.7M
YoY Change
Total Liabilities & Shareholders Equity	$103.6M	$110.4M	$120.3M
YoY Change	-9.11%	-8.24%	-17.93%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$11.10M	-$8.479M	-$8.864M
YoY Change	38.85%	-4.34%	52.19%
Depreciation, Depletion And Amortization	$2.670K	$630.00	$730.00
YoY Change	265.75%	-13.7%	-3.95%
Cash From Operating Activities	-$6.800M	-$9.583M	-$7.712M
YoY Change	7.39%	24.25%	60.02%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00		$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-550.0	13.80M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-6.800M	-9.583M	-7.712M
Cash From Investing Activities	0.000		0.000
Cash From Financing Activities	-550.0	13.80M	0.000
Net Change In Cash	-6.801M	4.216M	-7.712M
YoY Change	7.39%	-154.67%	-164.41%
FREE CASH FLOW
Cash From Operating Activities	-$6.800M	-$9.583M	-$7.712M
Capital Expenditures			$0.00
Free Cash Flow			-$7.712M
YoY Change			60.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153775380	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38174
	dei	Entity Registrant Name EntityRegistrantName	Citius Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3425913
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
	dei	City Area Code CityAreaCode	(908)
	dei	Local Phone Number LocalPhoneNumber	967-6677
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CTXR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	158857798	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33281830	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41711690	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7832320	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2852580	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	41114150	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	44564270	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2010	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4100	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	503817	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646074	usd
CY2023Q2	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2022Q3	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2023Q2	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2022Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	9346796	usd
CY2022Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	68784858	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	68784858	usd
CY2023Q2	us-gaap	Assets Assets	110404835	usd
CY2022Q3	us-gaap	Assets Assets	113999302	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3079667	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1165378	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	892874	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1405394	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1605445	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1762251	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	212871	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196989	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5790857	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4530012	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5993800	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5561800	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	320011	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481245	usd
CY2023Q2	us-gaap	Liabilities Liabilities	12104668	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10573057	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	158857798	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158857798	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	146211130	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	146211130	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	158858	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	146211	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	249828398	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	232368121	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152287469	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129688467	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	97699787	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	102825865	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	98300167	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110404835	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113999302	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3764675	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4888192	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11937045	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13798251	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3733326	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3024783	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11129463	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9038949	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1174111	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1003677	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3540787	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2929279	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	8672112	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8916652	usd
	us-gaap	Operating Expenses OperatingExpenses	26607295	usd
	us-gaap	Operating Expenses OperatingExpenses	25766479	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8672112	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8916652	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26607295	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25766479	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	336780	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	53020	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	854604	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	116573	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3585689	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	336780	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	53020	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4440293	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	116573	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8335332	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8863632	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22167002	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25649906	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	432000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-8479332	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-8863632	usd
	us-gaap	Profit Loss ProfitLoss	-22599002	usd
	us-gaap	Profit Loss ProfitLoss	-25649906	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153775380	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146129630	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148746002	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146061108	shares
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1201081	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-3593645	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101033681	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	102000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31267	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1165595	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-10526025	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91806518	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1201131	usd
CY2023Q2	ctxr	Issuance Of Common Stock In Registered Direct Offering IssuanceOfCommonStockInRegisteredDirectOffering	13798870	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1174111	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-8479332	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	98300167	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	132782733	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95884	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	904604	usd
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-9225220	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	124558001	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	178000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1020998	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-7561054	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	118195945	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1003677	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-8863632	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	110335990	usd
	us-gaap	Profit Loss ProfitLoss	-22599002	usd
	us-gaap	Profit Loss ProfitLoss	-25649906	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3540787	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2929279	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	273884	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	142257	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	131235	usd
	us-gaap	Depreciation Depreciation	2090	usd
	us-gaap	Depreciation Depreciation	2192	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	432000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4979740	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	48915	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1914289	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	413425	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-512520	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	679239	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	156806	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	628499	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-145352	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-130686	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22259997	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22028752	usd
	ctxr	Net Proceeds From Registered Direct Offering NetProceedsFromRegisteredDirectOffering	13798870	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31267	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13830137	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8429860	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-22028752	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41711690	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70072946	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33281830	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48044194	usd
CY2020Q3	us-gaap	Shares Issued SharesIssued	7500000	shares
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	19400000	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	40000000	usd
CY2023Q2	us-gaap	Goodwill Gross GoodwillGross	9346796	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates </i>— Our accounting principles require our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development and goodwill impairment, stock-based compensation, valuation of warrants, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p>
CY2023Q2	ctxr	Gross Proceeds GrossProceeds	15000001	usd
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	1.5
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11000000	usd
	ctxr	Negative Cash Flow Operations NegativeCashFlowOperations	-22259997	usd
CY2023Q2	ctxr	Working Capital WorkingCapital	35323293	usd
	ctxr	Annual Maintenance Cost AnnualMaintenanceCost	90000	usd
	ctxr	Annual Maintenance Cost AnnualMaintenanceCost	90000	usd
	us-gaap	Royalty Expense RoyaltyExpense	100000	usd
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	25000	usd
	ctxr	Maximum Aggregate Annual Royalties MaximumAggregateAnnualRoyalties	150000	usd
	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	1100000	usd
CY2023Q1	us-gaap	Cost Maintenance CostMaintenance	75000	usd
CY2022Q1	us-gaap	Cost Maintenance CostMaintenance	60000	usd
	ctxr	Milestone Payments MilestonePayments	2100000	usd
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2034-01-02
	ctxr	Developmental Milestones Payment DevelopmentalMilestonesPayment	51000000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.50	pure
	us-gaap	Payments For Fees PaymentsForFees	10000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	50201	shares
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	95884	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	100000	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	178000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	100000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	102000	usd
CY2023Q2	ctxr	Direct Offering Shares DirectOfferingShares	12500001	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	12500001	shares
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.2
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	13798870	usd
CY2023Q2	us-gaap	Other Ownership Interests Offering Costs OtherOwnershipInterestsOfferingCosts	15950	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	875000	usd
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.5
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	771000	usd
	ctxr	Stock Incentive Plan StockIncentivePlan	1240000	usd
CY2023Q2	ctxr	Option To Purchase Share Outstanding OptionToPurchaseShareOutstanding	300000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	11735000	shares
	ctxr	Sharebased Compensations Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P10Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9400171	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.07
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M21D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	869509	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4150000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.26
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46667	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	34067	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	123333	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.52
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13380171	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.79
	ctxr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M10D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	815287	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6200170	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.09
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M25D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	747453	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	50000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.04
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	75000	shares
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.42
CY2023Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	75000	shares
CY2023Q2	us-gaap	Employee Stock Ownership Plan Esop Effect On Earnings Per Share EmployeeStockOwnershipPlanESOPEffectOnEarningsPerShare	$1.46
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.98
CY2021Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	375000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.04
CY2021Q4	ctxr	Board Of Directors Granted Options To Purchase Shares BoardOfDirectorsGrantedOptionsToPurchaseShares	200000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.87
CY2022Q1	ctxr	Options To Purchase Shares OptionsToPurchaseShares	300000	shares
CY2022Q1	ctxr	Options To Purchase Shares OptionsToPurchaseShares	300000	shares
CY2022Q2	ctxr	Options To Purchase Shares OptionsToPurchaseShares	80000	shares
	ctxr	Share Issued Price Per Share ShareIssuedPricePerShare	1.67	shares
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1174111	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33333	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3540787	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	98524	usd
CY2023Q2	ctxr	Citius Stock Plans CitiusStockPlans	5925203	usd
	ctxr	Weighted Average Period Term WeightedAveragePeriodTerm	P1Y8M12D
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2000000	shares
	ctxr	Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber	1911500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	88500	shares
	ctxr	Stock Issued During Period Shares Stock Option Exercised StockIssuedDuringPeriodSharesStockOptionExercised	1911500	shares
CY2023Q2	ctxr	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Averag Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAveragExercisePrice	0.24
CY2023Q2	us-gaap	Shares Issued SharesIssued	1514333	shares
CY2023Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	79433	usd
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15000000	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	12550000	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.15
CY2023Q2	ctxr	Number Of Warrants Issued NumberOfWarrantsIssued	50923819	shares
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1747081	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	13380171	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	11735000	shares
	ctxr	Warrants Warrants	50923819	shares
	ctxr	Common Stock Reserved CommonStockReserved	76038990	shares
	ctxr	Schedule Lease Expense ScheduleLeaseExpense	The elements of lease expense are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Lease cost</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> June 30,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> June 30,<br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">179,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">179,116</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,567</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">772</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total lease cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">182,685</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">179,888</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average remaining lease term - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">2.3 Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">3.3 Years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table>
	us-gaap	Operating Lease Cost OperatingLeaseCost	179118	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	179116	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	3567	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	772	usd
	us-gaap	Lease Cost LeaseCost	182685	usd
	us-gaap	Lease Cost LeaseCost	179888	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q2	ctxr	Operating Lease Future Minimum Payments Due Current OperatingLeaseFutureMinimumPaymentsDueCurrent	61952	usd
CY2023Q2	ctxr	Operating Lease Future Minimum Payments Due In Three Years OperatingLeaseFutureMinimumPaymentsDueInThreeYears	249024	usd
CY2023Q2	ctxr	Operating Lease Future Minimum Payments Due In Four Years OperatingLeaseFutureMinimumPaymentsDueInFourYears	253883	usd
CY2023Q2	ctxr	Operating Lease Future Minimum Payments Due In Five Years OperatingLeaseFutureMinimumPaymentsDueInFiveYears	21460	usd
CY2023Q2	ctxr	Operating Lease Future Minimum Payments Due OperatingLeaseFutureMinimumPaymentsDue	586319	usd
CY2023Q2	ctxr	Less Interest LessInterest	53437	usd
CY2023Q2	ctxr	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	532882	usd
	ctxr	Schedule Operating Leases Assets And Liabilities ScheduleOperatingLeasesAssetsAndLiabilities	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Leases</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lease asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt">Operating</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">503,817</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">646,074</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total lease assets</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">503,817</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">646,074</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: center">Operating</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">212,871</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">196,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,011</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">481,245</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">532,882</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">678,234</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	503817	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646074	usd
CY2023Q2	ctxr	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	503817	usd
CY2022Q3	ctxr	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	646074	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	212871	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196989	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	320011	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481245	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	532882	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	678234	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	36861	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	47881	usd
	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	3585689	usd
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001506251

Files In Submission

Name	View Source	Status
ctxr-20230630_cal.xml	Edgar Link	unprocessable
f10q0623_citiuspharma_htm.xml	Edgar Link	completed
0001213900-23-067024-index-headers.html	Edgar Link	pending
0001213900-23-067024-index.html	Edgar Link	pending
0001213900-23-067024.txt	Edgar Link	pending
0001213900-23-067024-xbrl.zip	Edgar Link	pending
ctxr-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_citiuspharma.htm	Edgar Link	pending
f10q0623ex31-2_citiuspharma.htm	Edgar Link	pending
f10q0623ex32-1_citiuspharma.htm	Edgar Link	pending
f10q0623_citiuspharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
ctxr-20230630_def.xml	Edgar Link	unprocessable
ctxr-20230630_pre.xml	Edgar Link	unprocessable
ctxr-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

2023 Q3 Form 10-Q Financial Statement

#000121390023067024 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR Citius Pharmaceuticals, Inc. Stock $ctxr

2023 Q3 Form 10-Q Financial Statement

#000121390023067024 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr